Clinicians can now deliver in-lab quality sleep studies with fewer electrodes, faster setup, and no compromise in accuracy, in any location
Nox Medical—the global leader in sleep care management solutions, diagnostic technologies, and prescription digital therapeutics—today announced the U.S. launch of the Nox SAS™ solution: an advanced EEG technology that enables simplified, clinically rigorous PSG testing in any setting.
Designed for use with the Nox A1® PSG recorder, the Nox SAS solution eliminates the complexity of traditional PSG setups while maintaining clinical-grade signal quality. For sleep professionals facing staffing shortages, rising patient demand, or the need to extend services beyond the lab, Nox SAS offers an efficient, proven pathway to full PSG diagnostics with unmatched flexibility.
“Sleep care is evolving beyond the four walls of the lab”, said Sigurjon Kristinsson, CEO of Nox. “With Nox SAS, clinicians don’t have to choose between convenience and clinical rigor. This technology delivers both—opening the door to faster workflows, broader access, and better patient experiences.”
By using forehead-based EEG and EMG electrodes, Nox SAS reduces the need for scalp and chin electrode placement, simplifying setup and designed for patient comfort. This streamlined approach is particularly helpful for patients with facial hair, scalp sensitivities, or in low-resource environments where trained technicians may be limited.
When paired with the latest Nox A1 recorder, the solution captures EEG, EOG, EMG, and ECG signals with high fidelity, and works in tandem with the Nox calibrated RIP belts to deliver Nox Flow™—a true respiratory flow signal that enhances diagnostic accuracy.
Validated in over 6,000 global sleep studies and a multicenter U.S. study of more than 960 participants, Nox SAS achieved 85% first-attempt success rate and 88.6% overall success in self-applied Type II PSG testing—without technician support.3
“Nox SAS was built to meet the realities of modern sleep care—clinically precise with the simplicity needed to bring full PSG studies into the home,” said Sveinbjorn Hoskuldsson, Chief Technology Officer at Nox. “By rethinking the traditional PSG setup, we created a solution that delivers gold-standard diagnostics and fits effortlessly into existing workflows.”
The launch of Nox SAS comes as Type II PSG gains momentum as a scalable solution for both expanding access and increasing efficiency. Whether used to extend diagnostics beyond the lab or streamline workflows within it, Nox SAS delivers PSG-grade data without compromising clinical quality.
“Whether it’s used in-lab or in the home, Nox SAS allows providers to extend diagnostic capabilities without expanding staff,” said Dr. Heidi Riney, Chief Medical Officer at Nox. “This gives clinicians the tools they need to meet growing demand with confidence, accuracy, and ease.”
Already in use by academic researchers across the U.S., Nox SAS is now available for clinical deployment. With its simplified application and powerful signal performance, it supports hybrid and tech-light care models that preserve quality while increasing access.
Clinical Highlights of the Nox SAS™ Solution
- A simpler path to full polysomnography, used with the latest Nox A1 PSG recorder and Nox RIP belts to capture true respiratory flow and effort—Nox Flow™.
- Captures EEG, EMG, and ECG signals with high agreement to manually scored sleep stages in conventional PSG montage1,2
- Validated for both in-lab use and patient-applied home PSG testing (Type II)3,4
- Designed for time-saving and simplicity, enabling technicians to perform faster hookups without losing the precision clinicians expect.
- Reduces hookup complexity with fewer electrodes, no chin EMG, and tether-free design.
- Seamless integration with Noxturnal Software, the same platform used with Nox A1® PSG and Nox T3® HSAT, ensures continuity across diagnostic workflows.
1 Punjabi NM et al. Sleep. 2018;41:A122. doi:10.1093/sleep/zsy061.318
2 Rusanen M et al. J Sleep Res. 2023. doi:10.1111/jsr.13977
3 Punjabi NM et al. Sleep Adv. 2022;3(1):zpac011. doi:10.1093/sleepadvances/zpac011
4 Ferretti D et al. J Sleep Res. 2024. doi:10.1111/jsr.14286
Topic: Industry News
